C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice

European Psychiatry

Volumn 28, Issue 3, 2013, Pages 161-167

  Sicras Mainar, A ^a   Rejas Gutierrez J ^b   Navarro Artieda, R ^c   Blanca Tamayo, M ^d  

^a Directorate of Planning   (Spain)

^b PFIZER INC   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d NONE   (Spain)

Author keywords

C reactive protein; Cardiovascular risk; Framingham function; Real world; Schizophrenia spectrum disorders

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL CHEMISTRY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL PRACTICE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SEX RATIO; SMOKING; SOCIAL ASPECT;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA;

EID: 84875080929     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.07.003     Document Type: Article

References (50)

1. Alegría E., Cordero A., Laclaustra M., Grima A., León M., Casasnovas J.A., et al. en representación de los investigadores del registro MESYAS. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev Esp Cardiol 2005, 58:797-806.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC; 2000.
3. Bjerkeset O., Romild U., Smith G.D., Hveem K. The associations of high levels of C-reactive protein with depression and myocardial infarction in 9258 women and men from the HUNT population study. Psychol Med 2010, 6:1-8.
4. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90:162-173.
5. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotics drugs. J Clin Psychiatry 2006, 67:575-583.
6. Cunha A.B., Andreazza A.C., Gomes F.A., Frey B.N., da Silveira L.E., Gonçalves C.A., et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008, 258:300-304.
7. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397. 10.1056/NEJMoa032804.
8. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
9. Dehghan A., Kardys I., De Maat M.P., Uitterlinden A.G., Sijbrands E.J., Bootsma A.H., et al. Genetic variation. C-reactive protein levels, and incidence of diabetes. Diabetes 2007, 56:872.
10. Diaz F.J., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Vázquez-Barquero J.L., de Leon J., et al. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr Res 2010, 121:207-212.
11. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007, 93:261-265.
12. Dinan T.G. Inflammatory markers in depression. Curr Opin Psychiatry 2009, 22:32-36.
13. Douglas K.M., Taylor A.J., O'Malley P.G. Relationship between depression and C-reactive protein in a screening population. Psychosom Med 2004, 66:679-683.
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
15. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007, 149:267-271.
16. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target?. Can J Cardiol 2010, 26(Suppl. A):41A-44A.
17. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70:1078-1090.
18. Hagg S., Lindblom Y., Mjorndal T., Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006, 21:93-98.
19. Keltner N.L., Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006, 42:204-207.
20. Kones R. The Jupiter study. CRP screening and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Ther Adv Cardiovasc Dis 2009, 3:309-315.
21. Konnopka A., Klingberg S., Wittorf A., König H.H. The cost of schizophrenia in Germany: a systematic review of the literature. Psychiatr Prax 2009, 36:211-218.
22. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S.S., Magder L.S., Kreyenbuhl J., et al. Assessment of independent effect of olanzapina and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002, 325:243-245.
23. The International Classification of Primary Care in the European Community. With a multi-language layer 1993, Oxford University Press, Oxford. H. Lamberts, M. Wood, Hofmans-Okkes IM (Eds.).
24. Lawlor D.A., Bedford C., Taylor M., et al. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003, 57134-57140.
25. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
26. Marsik C., Kazemi-Shirazi L., Schickbauer T., Winkler S., Joukhadar C., Wagner O.F., et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008, 54:343-349.
27. Martínez M.A., Puig J.G., Mora M., Aragón R., O'Dogherty P., Antón J.L., et al. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid RIesgo Cardiovascular) Study. Metabolism 2008, 57:1232-1240.
28. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005, 80:19-32.
29. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008, 30:67-76.
30. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009, 66:1013-1022.
31. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009, 119:4-14.
32. Oud M.J., Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009, 10:32.
33. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., 3rd, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
34. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812. PMID 12813013. PMC 161431. 10.1172/JCI18921.
35. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334. 10.1001/jama.286.3.327.
36. Rejas J., Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 2008, 99:23-28.
37. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391-397.
38. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843. 10.1056/NEJM200003233421202.
39. Saha S., Chant D., McGrath J. Meta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues. Int J Methods Psychiatr Res 2008, 17:55-61.
40. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
41. Scheepers-Hoeks A.M., Wessels-Basten S.J., Scherders M.J., Bravenboer B., Loonen A.J., Kleppe R.T., et al. Schizophrenia and antipsychotics associated with the metabolic syndrome. An overview. Tijdschr Psychiatr 2008, 50:645-654.
42. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009, 35:5-8.
43. Strassnig M., Brar J.S., Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003, 29:393-397.
44. Timpson N.J., Lawlor D.A., Harbord R.M., Gaunt T.R., Day I.N., Palmer L.J., et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 2005, 366:1954-1959.
45. Usher K., Foster K., Park T. The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. J Psychiatr Ment Health Nurs 2006, 13:730-734.
46. Van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
47. Vuksan-Cusa B., Sagud M., Jakovljević M. C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr Danub 2010, 22:275-277.
48. Weis S., Haybaeck J., Dulay J.R., Llenos I.C. Expression of cellular prion protein (PrP(c)) in schizophrenia, bipolar disorder, and depression. J Neural Transm 2008, 115:761-771.
49. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
50. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897-1908. 10.1056/NEJMoa0707402.